

DAFTAR PUSTAKA

- Adeloye, D., Song, P., Zhu, Y., Campbell, H., Rudan, I. 2022, Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis, *The Lancet Respiratory Medicine*, **10**(5), pp. 447–458. Available at: [https://doi.org/10.1016/S2213-2600\(21\)00511-7](https://doi.org/10.1016/S2213-2600(21)00511-7).
- Almagro, P., Cosío, B. G., Soler-Cataluña, J. J., & González-Segura, D. 2024, Impact of comorbidities in COPD clinical control criteria: The CLAVE study, *BMC Pulmonary Medicine*, **24**(1), 6.
- AL Wachami, N., Guennouni, M., Iderdar, Y., Boumendil, K., Mourajid, Y., Arraji, M., dkk. 2024, Estimating the global prevalence of chronic obstructive pulmonary disease (COPD): A systematic review and meta-analysis, *BMC Public Health*, **24**(1), 297.
- Avdeev, S. N., Vizel, A. A., Abrosimov, V. N., Zaicev, A. A., Ignatova, G. L., Khamitov, R. F., dkk. 2022, Management of cough in patients with chronic obstructive pulmonary disease: Results of the multicenter randomized placebo-controlled clinical trial, *Therapeutic Archive*, **82**(3), 29–32. (Data as clinical trial report).
- Anil, A.A., Rajesh, D., Krishnan, A.L., Arun, C., Thomas, R., Chandra, P., Haridas N. 2024, Evaluating the mucolytic effectiveness of ambroxol and N-acetylcysteine in patients with acute exacerbation of chronic obstructive pulmonary disease, *Clinical Epidemiology and Global Health*, 2213-3984.
- Ansari, S.F., Memon, M., Brohi, N., Tahir, A. 2019, N-acetylcysteine in the Management of Acute Exacerbation of Chronic Obstructive Pulmonary Disease, *Cureus*, **11**(11): e6073.
- Bischof, A.Y., Cordier, J., Vogel, J., Geissler, A. 2024, Medication adherence halves COPD patients' hospitalization risk – evidence from Swiss health insurance data, *npj Prim. Care Respir. Med.*, **34**:1.
- Cazan, D., Klimek, L., Sperl, A., Plomer, M, Kolsch, S. 2018, Safety of ambroxol in the treatment of airway diseases in adult patients, *Expert Opin Drug Saf*, **17**:1211-24.
- Celli, B., Fabbri, L., Criner, G., Martinez, F.J., Mannino, D., Vogelmeier, C., Montes tryudfdfyudde Oca, M., Papi, A., Sin, D.D., Han, M.K., Agusti, A. 2022, Definition and nomenclature of Chronic Obstructive Pulmonary Disease: time for its revision, *Am J Respir Crit Care Med*, **206**(11):1317-25.

- Cho, P.S.P., Fletcher, H.V., Patel, I.S., Turner, R.D., Jolley, C.J., Birring, S.S. 2021, Cough hypersensitivity and suppression in COPD, *Eur Respir J*, **57**(5): 2003569.
- Chow, R., Pakhale, S., dkk. 2026, Sexually dimorphic response to tobacco exposure in COPD: A systematic review and meta-analysis, *BMC Pulmonary Medicine*, **26**, 45.
- D'Antonio, A., dkk. 2025, Mucolytic therapy in COPD: Patient usage and preferences in real-world Italian settings, *International Journal of Chronic Obstructive Pulmonary Disease*, **20**, 479–486.
- Davis, J.R., Wu, B., Kern, D.M., Tunceli, O., Fox, K.M., Horton, J., dkk. 2017, Impact of nonadherence to inhaled corticosteroid/LABA therapy on COPD exacerbation rates and healthcare costs in a commercially insured US population, *Am Health Drug Benefits*, **10**(2): 92-102.
- Donaldson, G.C., Seemungal, T.A., Bhowmik, A., Wedzicha, J.A. 2002, Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease, *Thorax*, **57**(10): 847-52.
- Deretic, V. & Timmins, G.S. 2019, Enhancement of lung levels of antibiotics by ambroxol and bromhexine, *Expert Opin Drug Metab Toxicol*, **15**:213-8.
- DiPiro, J. T., Talbert, R. L., Yee, G. C., Matzke, G. R., Wells, B. G., & Posey, L. M. 2024, *Pharmacotherapy: A Pathophysiologic Approach (12th ed.)*, McGraw-Hill Education.
- Fowdar, K., Chen, H., He, Z., Zhang, Jiujin, Zhong, X., Zhang, Jianquan, dkk. 2017, The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review, *Heart & Lung*, **46**: 120-128.
- Fragoso, C. A. V. 2016, Epidemiology of chronic obstructive pulmonary disease (COPD) in aging populations, *COPD: Journal of Chronic Obstructive Pulmonary Disease*, **13**(2), 125–129.
- George, S.N., Garcha, D.S., Mackay A.J., Patel, A.R.C., Singh, R., Raymond J.S., dkk. 2014, Human rhinovirus infection during naturally occurring COPD exacerbations, *Eur Respir J*, **44**(1):87-96.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2025, *Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report*.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2026, *Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2026 report*.

- Hsu, J.Y., Stone, R.A., Logan-Sinclair, R.B., Worsdell, M., Busst, C., & Chung, K.F. 1994, Cough frequency in asthma: Relationship to obstruction and bronchodilator reversibility, *Journal of Asthma*, **31**(4), 265-271.
- Iheanacho, I., Zhang, S., King, D., Rizzo, M., Ismaila, A.S. 2020, Economic burden of Chronic Obstructive Pulmonary Disease (COPD): a systematic literature review, *Int J Chron Obstruct Pulmon Dis*. **15**:439-60.
- Indreswari, Y.S., Rumende, C.M., dan Pitoyo, C.W. 2014, Faktor-faktor yang berhubungan dengan eksaserbasi pada pasien penyakit paru obstruktif kronik di Rumah Sakit Cipto Mangunkusumo, Jakarta, *Chest*, **1**(4): 160-165.
- Jones, P.W., Harding, G., Berry, P., Wiklund, I., Chen, W.H., & Leidy, N.K. 2009. Development and first validation of the COPD Assessment Test. *Eur Respir J*, **34**(3), 648-654.
- Jones, P.W., Tabberer, M., & Chen, W.H. 2012, Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT™) scores, *BMC Pulmonary Medicine*, **11**, 42.
- Kanner, R.E., Anthonisen, N.R., Connet, J.E. 2001, Lower respiratory illnesses promote FEV1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease, *Am J Respir Crit Care Med*. **164**(3):35864.
- Kantar, A., Klimek, L., Cazan, D., Sperl, A., Sent, U., dan Mesquita, M. 2020, An overview of efficacy and safety of ambroxol for the treatment of acute and chronic respiratory diseases with a special regard to children, *Multidisciplinary Respiratory Medicine*, **15**: 511.
- Kementerian Kesehatan Republik Indonesia. 2023. *Panduan Nasional Praktik Kedokteran: Penyakit Paru Obstruktif Kronik (PPOK)*. Jakarta: Direktorat Pelayanan Kesehatan Rujukan.
- Kemenkes RI. 2018. *Riset Kesehatan Dasar. Badan Penelitian dan Pengembangan Kementrian Kesehatan Republik Indonesia*, Jakarta.
- Kolarov, V., Stevuljevi, J.K., Ili, M., Bogdan, M., Tušek, B., Agic, A., dkk. 2022, Factorial analysis of N-acetylcysteine and propolis treatment effects on symptoms, life quality and exacerbations in patients with chronic obstructive pulmonary disease (COPD): a randomized, double-blind, placebo-controlled trial, *European Review for Medical and Pharmacological Sciences*.
- Kuzmenko, N., Iaremenko, O., Dobrianskiy, D., Ilnytskyi, R., & Gumeniuk, G. 2020, The efficacy and safety of inhaled acetylcysteine in comparison with oral acetylcysteine in chronic obstructive pulmonary disease: A randomized single-center study, *Polish Annals of Medicine*, **27**(2), 108–114.

- Kwok, W.C., Chan, S.K.S., Chiang, K.Y., Ho, C.M.J. 2024, A double-blind randomized controlled trial of N-acetylcysteine (NAC) for the treatment of acute exacerbation of chronic obstructive pulmonary disease, *Respirology Case Report*, **12**:e01449.
- Kwon, J.-W., Moon, J.-Y., Kim, Sae-Hoon, Song, W.-J, Kim, M.-H., Kang, M.-G., dkk. 2017, Korean version of the cough symptom score: clinical utility and validity for chronic cough, *The Korean Journal of Internal Medicine*, **32**: 910-915.
- Lemeshow, S., Hosmer, D.W., Klar, J., dan Lwanga, S.K. (Editor). 1990, *Adequacy of Sample Size in Health Studies*. Published on behalf of the World Health Organization by Wiley; Distributed in the U.S.A., Canada, and Japan by Liss, England.
- Li, Z. 2021, The effect of adjuvant therapy with ambroxol hydrochloride in elderly chronic obstructive pulmonary disease patients, *Am J Transl Res*, **13**(8):9285-9295.
- Li, Y., Li, J., & Yu, H. 2025, Effect of triple therapy on mortality and cardiovascular risk in patients with moderate to severe COPD. *BMC Pulmonary Medicine*, **25**, 345.
- Liu, H., Wang, W., dan Gao X. 2020, Comparison of the efficacy of ambroxol hydrochloride and N-acetylcysteine in the treatment of the children with bronchopneumonia and their influence on prognosis, *Experimental and Therapeutic Medicine*, **20**: 130.
- López-Denis, M., Cálamo-Guzmán, B., Castillo-Corullón, S., Carrasco-Luna, J., Herrero, M. J., González-Villaescusa, C., Signes-Costa, J., dkk. 2026, Antioxidants as therapeutic tools in the management of COPD: A systematic review with meta-analysis, *Antioxidants*, **15**(4), 446.
- Malerba, M., Ponticiello, A., Radaeli, A., Bensi, G., dan Grassi, V. 2004, Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD: Double-blind, randomized, multicenter, placebo-controlled study, *Pulmonary Pharmacology & Therapeutics*, **17**: 27-34.
- Miravittles, M., Kawayama, T., & Dreher, M. 2022, LABA/LAMA as first-line therapy for COPD: A summary of the evidence and guideline recommendations, *Journal of Clinical Medicine*, **11**(22), 6623.
- Molidia, S. R., Pramantara, D. P., & Ikawati, Z. 2024, Comparison of clinical outcomes between acetylcysteine and ambroxol in post-acute exacerbation of COPD patients, *Jurnal Sains Farmasi & Klinis*, **11**(1), 58-66.

- Orozco-Levi, M., Colmenares-Mejía, C., Ruíz, J., Valencia-Barón, Y. D., Ramírez-Sarmiento, A., Quintero-Lesmes, D. C., & Serrano, N. C. 2021, Effect of antioxidants in the treatment of COPD patients: Scoping review, *Journal of Nutrition and Metabolism*, 2021, Article 7463391.
- Papadopoulou, E., Hansel, J., Lazar, Z., Kostikas, K., Tryfon, S., Vestbo, J., dkk. 2023, Mucolytics for acute exacerbations of chronic obstructive pulmonary disease: a Meta-analysis, *European Respiratory Review*, **32**: 220141.
- Papi, A., Avdeev, S., Calverley, P.M.A., Cordeiro, C.R., Jesenak, M., Koblížek, V., dkk. 2020, Use of Mucolytics in COPD: A Delphi Consensus Study, *Respiratory Medicine*, **175**: 106190.
- Papi, A., Di Stefano, A.F.D., & Radicioni, M. 2021, Pharmacokinetics and safety of single and multiple doses of oral n-acetylcysteine in healthy chinese and caucasian volunteers: an open-label, phase I clinical study, *Adv in Therapy*, **38**(1):468-478.
- Poole, P., Sathananthan, K., dan Fortescue, R. 2019, Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. *Cochrane Database of Systematic Reviews*.
- Perhimpunan Dokter Paru Indonesia (PDPI). 2023, *Penyakit Paru Obstruktif Kronis (PPOK): Pedoman diagnosis dan penatalaksanaan di Indonesia*, Jakarta.
- Ritchie, A.I. & Wedzicha, J.A. 2020, Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations, *Clin Chest Med*. **41**: 421-438.
- Rogliani, P., Manzetti, G.M., Gholamalishahi, S., Cazzola, M., Calzetta, L. 2024, Impact of N-Acetylcysteine on Mucus Hypersecretion in the Airways: A Systematic Review. *Int J Chron Obstruct Pulmon Dis*. 19: 2347-2360.
- Sanguinetti, C.M. 2016, N-acetylcysteine in COPD: Why, How, and When?, *Multidisciplinary Respiratory Medicine*, **11**:8.
- Sari, C.P., Hanifah, S., Rosdiana, R., dan Anisa, Y. 2021, Efektivitas pengobatan pada pasien penyakit paru obstruksi kronis (PPOK) di rumah sakit wilayah Yogyakarta, *Jurnal Manajemen dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice)*, **11**: 215.
- Skajaa, N., Laugesen, K., Horváth-Puhó, E., & Sørensen, H. T. 2023, Comorbidities and mortality among patients with chronic obstructive pulmonary disease. *BMJ Open Respiratory Research*, 10(1), e001798.
- Stanford, R. H., Tseng, M. A., & Mannino, D. M. 2020, Assessment of the COPD Assessment Test within U.S. Primary Care, *Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation*, 1(1), 127-134.

- Sushko, V., Shvaiko, L., Bazyka, K., dan Riazhska, A. 2016, Treatment of chronic obstructive pulmonary disease in clean-up workers of the Chornobyl NPP accident in the remote period after irradiation with additional 6 month prescription combination of ambroxol and essential phospholipids, *Eur Respir J*, **48**:60.
- Suzuki, Y., Sato, K., Sato, S., Inoue, S., Shibata, Y. 2024, Antibiotic treatment for patients with exacerbation of chronic obstructive pulmonary disease: A systematic review and meta-analysis, *Respiratory Investigation*, **62**(4), 663–668.
- Torres-Robles, A., Benrimoj, S.I., Gastelurrutia, M.A., Martinez-Martinez, F., Peiro, T., Perez-Escamilla, B., dkk. 2022, Effectiveness of a medication adherence management intervention in a community pharmacy setting: a cluster randomised controlled trial, *BMJ Qual Saf*, **31**(2): 105-115.
- UpToDate. 2025, *Ambroxol: International drug information (concise)*. Diakses pada 30 April 2025, <https://www.uptodate.com/>.
- Wang, K., Birring S.S., & Taylor, K. 2019, Types and applications of cough-related questionnaires, *Journal of Thoracic Disease*, **11**(17): S2020-S2027.
- WHO. 2024, *Chronic Obstructive Pulmonary Disease (COPD)*. Diakses pada 16 Februari 2025, [https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-\(copd\)](https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)).
- WHO. 2024, *Noncommunicable disease*. Diakses pada 16 Februari 2025, <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases>.
- Zheng J.P., Wen, F.Q., Bai, C.X., Wan, H.Y., Kang, J., Chen, P., dkk. 2014, Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial, *Lancet Respir Med*, **2**: 187-94.
- Zhou, Y., Wu, F., Shi, Z., Cao, J., Tian, J., Yao, W., Wei, L., dkk. 2024, Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicenter randomised clinical trial, *Nature Communications*, **15**: 8468.